ERBB2 and breast carcinoma: Among these, the luminal B subtype with HER2 positivity—where ER and PR are positive, and HER2 is amplified or overexpressed—is known as triple-positive breast cancer (TPBC), representing approximately 10% to 15% of all breast cancers (8).